HGH Peptides, Class by Class: How Growth Hormone Secretagogues Actually Work

Search "HGH peptides" and you'll find a dozen compounds lumped together as if they were interchangeable. They aren't. Almost none of them are actually growth hormone — and the differences between them are the whole point. This note walks through how these molecules work, sorts them into the two families researchers actually use, and lays out the advantages and disadvantages of each. As always, everything here is research context: nothing below is medical advice or a claim of safety or efficacy in people.

First, a definition problem: "HGH" vs. the peptides that trigger it

Real human growth hormone — recombinant somatropin — is the intact 191-amino-acid hormone itself, manufactured and administered directly. It's a prescription biologic, and it's not what this category is about. The peptides people call "HGH peptides" are growth hormone secretagogues (GHSs): they don't supply GH at all. Instead they signal the pituitary to release its own stored growth hormone [5]. That single distinction — replacing the hormone versus asking the body to make it — drives every advantage and disadvantage that follows.

How the pituitary decides to release GH

Growth-hormone release is governed by a push-and-pull system. GHRH (growth-hormone-releasing hormone) is the accelerator; somatostatin is the brake; and a second, independent accelerator runs through the ghrelin / GH-secretagogue receptor (GHS-R) — the receptor whose natural ligand, ghrelin, was identified in the stomach in 1999 [1]. Because there are two separate "on" switches, there are two separate drug classes, and the fact that the body keeps its brake (somatostatin) and its feedback loops intact is exactly why secretagogues tend to preserve the natural, pulsatile rhythm of GH release rather than flooding the system [5].

Class 1 — GHRH analogs (the "natural signal" family)

These mimic the body's own GHRH instruction. Because they work upstream and leave feedback intact, they're generally described as the more physiologic of the two classes. Three show up most often:

Sermorelin — a 29-amino-acid fragment that is the shortest piece of GHRH with full activity [5].

• Advantages: closest to the native signal; decades of use as a diagnostic agent for GH deficiency; clean hormonal profile.
• Disadvantages: very short half-life (roughly 11–12 minutes), so the signal is brief and dosing is frequent [5].

CJC-1295 — a GHRH analog engineered to last far longer.

• Advantages: a single injection produced dose-dependent rises in GH and IGF-I lasting days rather than hours in healthy adults — a sustained signal instead of a spike [ref: see draft #05].
• Disadvantages: a longer, flatter signal is less like natural pulsatile release; and combination products built around it lack rigorous human trials.

Tesamorelin — a stabilized GHRH analog and the most clinically validated peptide in this entire category.

• Advantages: the only GHRH analog with FDA approval (for HIV-associated visceral fat accumulation), backed by large Phase III trials that showed selective reduction of visceral adipose tissue versus placebo, with IGF-I rising as expected [2].
• Disadvantages: its rigorous evidence is specific to one narrow population; it still requires daily subcutaneous injection; and it is comparatively expensive.

Class 2 — Ghrelin-receptor agonists / GHRPs (the "second door")

These act through GHS-R, the ghrelin pathway — a completely different receptor from GHRH. Historically these growth-hormone-releasing peptides (GHRPs) came before ghrelin; ghrelin was actually discovered as the natural ligand the synthetic peptides had been hitting all along [1].

Ipamorelin — the selectivity standout of the class.

• Advantages: in its original 1998 characterization it released GH cleanly, without the meaningful rises in ACTH, cortisol, or prolactin seen with earlier GHRPs — even at doses far above the effective range [ref: see draft #05]. That clean profile is why it became a research favorite.
• Disadvantages: short-acting and injectable; on its own it delivers a brief pulse rather than a sustained signal.

GHRP-2 and GHRP-6 — older, more potent, less tidy.

• Advantages: strong GH-releasing potency; GHRP-6 in particular is a robust stimulus.
• Disadvantages: less selective than Ipamorelin — they can nudge cortisol and prolactin, and both (GHRP-6 especially) tend to drive hunger through the same ghrelin pathway, which can be a confound in research settings.

The oral outlier — MK-677 (ibutamoren)

MK-677 doesn't fit neatly in either injectable family: it's a non-peptide, orally active, long-lasting agonist of the same ghrelin receptor. In a two-year randomized trial in healthy older adults, it raised GH and IGF-I into the young-adult range while preserving the normal pulsatile pattern, and it increased fat-free mass [3].

• Advantages: oral dosing (no injection) and a sustained, once-daily signal — practically unique in this category.
• Disadvantages: the same trial reported decreased insulin sensitivity and higher blood glucose, plus increased appetite and fluid retention [3]. Those metabolic trade-offs are the recurring caution in the GHS literature [4].

Why researchers combine a GHRH analog with a GHRP

Because the two classes hit two different receptors, they're often studied together on the hypothesis that the effect is additive — two doors into the same room. The Ipamorelin + CJC-1295 pairing is the classic example, and we cover the mechanism of that specific combination in detail in its own note. The short version: a long, GHRH-style "release" signal plus a clean, short ghrelin-pathway pulse is the pharmacological logic behind the blends [5].

Emerging research and where the promise is

The most promising recent work sits with the best-validated compounds. Tesamorelin's evidence base has expanded from visceral fat toward liver-fat and cardiometabolic endpoints, making it the reference point for what a GHRH analog can do when it's actually put through controlled human trials [2][5]. On the ghrelin side, MK-677's ability to restore youthful GH/IGF-I profiles keeps it in the conversation for sarcopenia and aging research — with the insulin-sensitivity caveat firmly attached [3]. And selective agents like Ipamorelin continue to be attractive precisely because they isolate the GH signal from the hormonal noise of older peptides [4]. The throughline: the excitement is real, but it tracks the compounds that have been tested most rigorously — not the ones with the loudest marketing.

Keeping it honest

Here's the caveat that applies to the whole category. "Raises GH and IGF-I in a study" is a long way from any claim about outcomes, safety, or benefit — and combination products in particular lack rigorous trials [4]. Restoring GH is not automatically desirable, and the metabolic trade-offs seen with some of these compounds are a reminder that more signal is not the same as better health. We supply these peptides strictly for in-vitro and laboratory research use only, and nothing above is medical advice or a claim of human efficacy.